The 2nd T-Cell Engager for Autoimmune Disease Summit arrives at a pivotal moment for the field as autoimmune TCEs rapidly transition from oncology-inspired concepts into one of the industry’s most exciting and heavily invested therapeutic modalities. Following major investments and partnerships from companies including Gilead, UCB, Sanofi, and Boehringer Ingelheim, the momentum around T-cell-directed approaches continues to accelerate. Most recently, Boehringer Ingelheim committed up to $15 million to a discovery collaboration with Immunai, using its single-cell AI platform to identify novel targets associated with dysfunctional T cells across cancer and autoimmune disease. This highlights the growing industry focus on understanding T-cell biology, identifying actionable targets, and leveraging patient-derived data to advance next-generation immune therapies.

As the industry’s only dedicated meeting focused exclusively on autoimmune T-cell engagers, this summit brings together 80+ leaders across discovery, translational, preclinical, clinical, and business development to tackle the field’s most urgent challenges. Discussions will explore how to reduce CRS toxicities, improving tissue-selective immune depletion, engineering next-generation engager architectures, and expanding beyond B-cell targets, the programme will address the practical challenges increasingly shaping clinical development. Additionally, discussions will include patient recruitment, particularly where patients already have effective standard-of-care options and may be hesitant to enter trials with uncertain efficacy or safety profiles, as well as biomarker selection and patient stratification to identify the right populations, predict responders, and improve clinical trial design. Discussions will explore how emerging translational insights, patient-derived data, and precision biomarker strategies can help bridge the gap between promising T-cell engager biology and successful clinical development.

With 15+ new speakers, emerging clinical datasets, 2 deep-dive workshops, and 8+ hours of networking including speed networking and interactive roundtables, this is the forum for the field to benchmark strategies, build partnerships, and exchange insights on the next generation of autoimmune T-cell engager development.